Across TCGA pan-cancer cohorts, LRIG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LRIG2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LRIG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LRIG2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, HNSC, and GBM are the cancer types where LRIG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	1.000	0.589	.016	20	view →
HNSC	OS	Tertile	All	0.663	1.000	.009	10	view →
GBM	OS	Tertile	All	0.524	0.273	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LRIG2 tumor-vs-normal RNA expression · all LRIG2 data types